Abstract
Dopamine agonists have been usually used as adjunctive therapy for the cure of Parkinsons disease. It is generally believed that treatment with these drugs is symptomatic rather than curative and it does not stop or delay the progression of neuronal degeneration. However, several dopamine agonists of the D2-receptor family have recently been shown to possess neuroprotective properties in different in vitro and in vivo experimental Parkinsons disease models. Here we summarize some recent molecular evidences underlining the wide pharmacological spectrum of dopamine agonists currently used for treating Parkinsons disease patients. In particular, the mechanism of action of different dopamine agonists does not always appear to be restricted to the stimulation of selective dopamine receptor subtypes since at least some of these drugs are endowed with antioxidant, antiapoptotic or neurotrophic properties. These neuroprotective activities are molecule-specific and may contribute to the clinical efficacy of these drugs for the treatment of chronic and progressive neurodegenerative diseases in which oxidative injury and/or protein misfolding and aggregation exert a primary role.
Keywords: Free radicals, oxidative stress, Parkinson's disease, Alzheimer's disease, beta amyloid, neurodegeneration, fibrils, neurotrophic factors, neurogenesis
Current Topics in Medicinal Chemistry
Title: Dopamine Receptor Agonists for Protection and Repair in Parkinsons Disease
Volume: 8 Issue: 12
Author(s): Giulia Ferrari-Toninelli, Sara A. Bonini, Giovanna Cenini, Giuseppina Maccarinelli, Mariagrazia Grilli, Daniela Uberti and Maurizio Memo
Affiliation:
Keywords: Free radicals, oxidative stress, Parkinson's disease, Alzheimer's disease, beta amyloid, neurodegeneration, fibrils, neurotrophic factors, neurogenesis
Abstract: Dopamine agonists have been usually used as adjunctive therapy for the cure of Parkinsons disease. It is generally believed that treatment with these drugs is symptomatic rather than curative and it does not stop or delay the progression of neuronal degeneration. However, several dopamine agonists of the D2-receptor family have recently been shown to possess neuroprotective properties in different in vitro and in vivo experimental Parkinsons disease models. Here we summarize some recent molecular evidences underlining the wide pharmacological spectrum of dopamine agonists currently used for treating Parkinsons disease patients. In particular, the mechanism of action of different dopamine agonists does not always appear to be restricted to the stimulation of selective dopamine receptor subtypes since at least some of these drugs are endowed with antioxidant, antiapoptotic or neurotrophic properties. These neuroprotective activities are molecule-specific and may contribute to the clinical efficacy of these drugs for the treatment of chronic and progressive neurodegenerative diseases in which oxidative injury and/or protein misfolding and aggregation exert a primary role.
Export Options
About this article
Cite this article as:
Ferrari-Toninelli Giulia, Bonini A. Sara, Cenini Giovanna, Maccarinelli Giuseppina, Grilli Mariagrazia, Uberti Daniela and Memo Maurizio, Dopamine Receptor Agonists for Protection and Repair in Parkinsons Disease, Current Topics in Medicinal Chemistry 2008; 8 (12) . https://dx.doi.org/10.2174/156802608785161402
DOI https://dx.doi.org/10.2174/156802608785161402 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Chemistry Based on Natural Products for Therapeutic Purposes
The development of new pharmaceuticals for a wide range of medical conditions has long relied on the identification of promising natural products (NPs). There are over sixty percent of cancer, infectious illness, and CNS disease medications that include an NP pharmacophore, according to the Food and Drug Administration. Since NP ...read more
Current Trends in Drug Discovery Based on Artificial Intelligence and Computer-Aided Drug Design
Drug development discovery has faced several challenges over the years. In fact, the evolution of classical approaches to modern methods using computational methods, or Computer-Aided Drug Design (CADD), has shown promising and essential results in any drug discovery campaign. Among these methods, molecular docking is one of the most notable ...read more
Drug Discovery in the Age of Artificial Intelligence
In the age of artificial intelligence (AI), we have witnessed a significant boom in AI techniques for drug discovery. AI techniques are increasingly integrated and accelerating the drug discovery process. These developments have not only attracted the attention of academia and industry but also raised important questions regarding the selection ...read more
From Biodiversity to Chemical Diversity: Focus of Flavonoids
Flavonoids are the largest group of polyphenols, plant secondary metabolites arising from the essential aromatic amino acid phenylalanine (or more rarely from tyrosine) via the phenylpropanoid pathway. The flavan nucleus is the basic 15-carbon skeleton of flavonoids (C6-C3-C6), which consists of two phenyl rings (A and B) and a heterocyclic ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Role of Glioma-associated GLI1 Oncogene in Carcinogenesis and Cancertargeted Therapy
Current Cancer Drug Targets Meet Our Editor
Central Nervous System Agents in Medicinal Chemistry Complications Associated with Recombinant Tissue Plasminogen Activator Therapy for Acute Ischaemic Stroke
CNS & Neurological Disorders - Drug Targets From Proteomic Studies to Molecular Pathways - Proteins Involved in Response to Methamphetamine Administration
Current Proteomics Structural Analysis and Comparison of Active Site Architecture from Ancient Bacteria to Human Phosphatases: A Novel Approach to Identification of Lead Compounds with Increased Specificity and Potency for Drug Discovery
Current Physical Chemistry Strategies for the Design of Non-peptide CCK2 Receptor Agonist and Antagonist Ligands
Current Topics in Medicinal Chemistry Metabotropic Glutamate Receptors as Drug Targets
Current Drug Targets Chromatin Changes Associated with Neuronal Maintenance and Their Pharmacological Application
Current Neuropharmacology Quantitative Measurement of Some Physico-Chemical Parameters for the Medicinally Useful Natural Products
Letters in Drug Design & Discovery Matrix Metalloproteinases as Potential Targets in the Venous Dilation Associated with Varicose Veins
Current Drug Targets Part-Time α-Secretases: The Functional Biology of ADAM 9, 10 and 17
Current Alzheimer Research Statins and Protein Prenylation in Cancer Cell Biology and Therapy
Anti-Cancer Agents in Medicinal Chemistry An Overview of High-grade Glioma: Current and Emerging Treatment Approaches
Current Cancer Therapy Reviews Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics
Current Neuropharmacology Effects of Early Maternal Separation on Biobehavioral and Neuropathological Markers of Alzheimer's Disease in Adult Male Rats
Current Alzheimer Research The Migraine-Ischemic Stroke Connection: Potential Pathogenic Mechanisms
Current Molecular Medicine A Review of the Three-Dimensional Cell Culture Technique: Approaches, Advantages and Applications
Current Stem Cell Research & Therapy PET Imaging of Norepinephrine Transporters
Current Pharmaceutical Design The Effects of Newer Beta-Adrenoceptor Antagonists on Vascular Function in Cardiovascular Disease
Current Vascular Pharmacology Clearance of Amyloid-β Peptide by Neuronal and Non-Neuronal Cells: Proteolytic Degradation by Secreted and Membrane associated Proteases
Current Neurovascular Research